1 / 8

DIGITAL THERAPEUTICS MARKET

The report "Digital Therapeutics (DTx) Market by Application (Prediabetes, Nutrition, Care, Diabetes, CVD, CNS, CRD, MSD, GI, Substance Abuse, Rehabilitation), Sales Channel B2C (Patient, Caregiver), B2B ( Providers, Payer, Employer, Pharma) - Global Forecasts to 2027", is projected to reach USD 17.7 billion by 2027 from USD 4.5 billion in 2022, at a CAGR of 31.6%.

johnny18
Télécharger la présentation

DIGITAL THERAPEUTICS MARKET

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Digital Therapeutics (DTx) Market  Global Forecast to 2027 Digital Therapeutics (DTx) Market is expected to reach $17.7 Billion by 2027 Growing at a CAGR of 31.6% (2022 – 2027) Request Sample

  2. Digital Therapeutics (DTx) Market worth $17.7 billion by 2027 MARKET OPPORTUNITY OVER NEXT 5 YEARS KEY MARKET PLAYERS TWO OF THE KEY DRIVERS OF THE MARKET WILL BE: CAGR of 31.6 2022-2027 • Noom, Inc (US) • Teladoc Health, Inc. (US) • Omada Health, Inc. (US) CAGR • Need to control healthcare costs North America commanded the largest share of the digital therapeutics market Market Segmentation by Equipment category: • By application, treatment/care-related applications form the largest segment of the digital therapeutics market • The B2B segment is the largest and fastest-growing segment of the market during the forecast period. Growth in this market is primarily driven by the government initiatives to support technological developments, and advancements in the field of digital therapeutics to curb growing healthcare costs.

  3. Medical Device Reprocessing Market worth $3.9 billion by 2027 The report "Digital Therapeutics (DTx) Market by Application (Prediabetes, Nutrition, Care, Diabetes, CVD, CNS, CRD, MSD, GI, Substance Abuse, Rehabilitation), Sales Channel B2C (Patient, Caregiver), B2B ( Providers, Payer, Employer, Pharma) - Global Forecasts to 2027", is projected to reach USD 17.7 billion by 2027 from USD 4.5 billion in 2022, at a CAGR of 31.6%. Browse 190 market data Tables and 33 Figures spread through 231 Pages and in-depth TOC on "Digital Therapeutics (DTx) Market by Application (Prediabetes, Nutrition, Care, Diabetes, CVD, CNS, CRD, MSD, GI, Substance Abuse, Rehabilitation), Sales Channel B2C (Patient, Caregiver), B2B ( Providers, Payer, Employer, Pharma) - Global Forecasts to 2027“ View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/digital-therapeutics-market-51646724.html

  4. Medical Device Reprocessing Market worth $3.9 billion by 2027 The digital therapeutics market is mainly driven by factors such as increasing investments in digital therapeutics, rising incidence of preventable chronic diseases, increasing government initiatives to support technological developments, and developments in the field of digital therapeutics to curb growing healthcare costs. However, hesitancy among patients to adopt digital therapeutics, and uneven payment models are challenging the growth of this market. Treatment/care-related applications segment is expected to account for the largest share of the digital therapeutics market in 2022 Based on application digital therapeutics market is segmented into preventive and treatment/care-related applications. The treatment/care-related applications segment is expected to hold the largest share of this market in 2022. The growth of this segment is primarily attributed to the increasing healthcare costs, the rising prevalence of chronic diseases, and the ability of digital therapeutics to deliver cost-effective solutions.

  5. Medical Device Reprocessing Market worth $3.9 billion by 2027 B2B segment is estimated to account for the largest share of the digital therapeutics market Based on sales channel, digital therapeutics market is segmented into business-to-customer (B2C) and business-to-business (B2B). The B2B segment is estimated to account for the largest share of the digital therapeutics market in 2022. Factors such as increasing partnership between many leading digital therapeutics provider companies and payers, providers, and employers to enhance their customer base are driving the B2B sales of digital therapeutics solutions. North America is expected to hold the largest share of the digital therapeutics market in 2022 The digital therapeutics market has been segmented into four main regional segments: North America, Europe, the Asia Pacific, and Rest of the World. North America is expected to hold the largest share of this market, followed by Europe in 2022. The market in North America is also expected to grow at the highest CAGR. The large share can be attributed to the rising number of new start-ups in digital therapeutics market and slowly developing reimbursement structures for digital therapeutics solutions.

  6. Medical Device Reprocessing Market worth $3.9 billion by 2027 Prominent players in the digital therapeutics market include Noom, Inc (US), Teladoc Health, Inc. (US), Omada Health, Inc. (US), WellDoc, Inc (US), Pear Therapeutics, Inc. (US), CogniFit Inc (US), Ginger (US), Propeller Health (US), 2Morrow, Inc. (US), Canary Health (US), Click Therapeutics, Inc. (US), Akili, Inc. (US), Cognoa, Inc (US), Wellthy Therapeutics Pvt. Ltd. (India), Twill Inc. (US), Better Therapeutics, Inc (US), Mindstrong (US), Kaia Health (Germany), BehaVR Inc (US), Ayogo (Canada), Mindable Health GmbH (Germany), Virta Health Corp (US), Hinge Health, Inc. (US), Orexo AB (Sweden) and Freespira (US). Don’t miss out on business opportunities in Digital Therapeutics (DTx) Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

  7. About MarketsandMarkets™ MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

  8. Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA : 1-888-600-6441 sales@marketsandmarkets.com

More Related